Amgen Inc. - Investor-Grade Deep Dive Research Report

Prepared for: Ada Health CEO
Date: March 11, 2026
Report Type: Comprehensive Pharmaceutical Company Analysis with Ada Patient Finder Opportunity Assessment

Executive Summary

Company Overview

Amgen Inc. (NASDAQ: AMGN) is an American multinational biopharmaceutical company headquartered at 1 Amgen Center Drive, Thousand Oaks, California 91320. Founded in 1980 as Applied Molecular Genetics (AmGen), the company has grown into one of the world's leading biotechnology firms, ranked 18th among the largest biomedical companies by revenue.

Employee Count: Approximately 24,000+ professionals worldwide as of 2025.

Key Financial Metrics (Fiscal Year 2025)

Total Revenue

$36.8B

+10% YoY

EBITDA Margin

44.0%

Non-GAAP Operating

Net Income (GAAP)

$7.7B

+88% YoY

Employees

24,000+

Global workforce

Forward-Looking Disclaimer: This report contains forward-looking statements based on current expectations and available data as of March 2026. Actual results may differ materially due to risks outlined in the Risks section, including competitive dynamics, regulatory outcomes, clinical trial results, pricing pressure, biosimilar competition, patent expirations, pipeline execution, and macroeconomic factors.

Revenue Mix by Segment (2025)

2025 Revenue Breakdown by Therapeutic Area

Revenue Growth Trajectory (2021-2025)

Five-Year Revenue Growth

Ada Patient Finder Analysis: Top Opportunities

The following table summarizes the highest-value opportunities for Ada Patient Finder across Amgen's portfolio:

Drug	Indication	Fit Score	Net Revenue/Patient	Undiagnosed Pop.	Annual Opportunity
UPLIZNA Tier 1	Generalized myasthenia gravis	8/10	$200-220K/year	20-30K (1-2 yr delays)	$80-176M
TEPEZZA Tier 1	Thyroid eye disease	8/10	$300-350K/course	20-30K undertreated	$240-420M
KRYSTEXXA Tier 2	Refractory chronic gout	7/10	$100-120K/course	150-250K underrecognized	$400-960M
Repatha Tier 3	Familial hypercholesterolemia	6/10	$2.5-3K/year	1.28-1.48M (>98%)	$25-100M (flat fee)
TEZSPIRE Tier 3	Severe uncontrolled asthma	6/10	$22-25K/year	900K-1.35M	$150-500M (flat fee)

Key Takeaways

Total Addressable Opportunity: $895M - $2,156M annually across all tiers at scale
Tier 1 (Strong Fit): UPLIZNA and TEPEZZA offer $320-596M combined opportunity with net revenue per patient >$200K
Tier 2 (Good Fit): KRYSTEXXA provides $400-960M opportunity with first-mover monopoly positioning
Recommended Priority: Engage Amgen Rare Disease franchise leadership on Tier 1 opportunities

Why These Drugs Fit Ada Patient Finder

UPLIZNA (Generalized Myasthenia Gravis)

Diagnostic Delay: 1-2 years median from symptom onset to MG diagnosis; 48% initially misdiagnosed
Symptom Signature: Ptosis (drooping eyelids) + diplopia (double vision) + fluctuating muscle weakness
Ada Detection: High capability to surface MG via classic triad of symptoms
Revenue: $200-220K/year net per patient; 73% YoY growth in 2025

TEPEZZA (Thyroid Eye Disease)

Referral Delays: 20-30K undertreated patients with delays from endocrinology to ophthalmology
Symptom Signature: Eye bulging + double vision + eye pain in Graves' disease patients
Ada Detection: High capability in patients with known Graves' disease/hyperthyroidism
Revenue: $300-350K per course; first-and-only FDA-approved treatment (monopoly)

KRYSTEXXA (Refractory Chronic Gout)

Underrecognition: 150-250K patients with uncontrolled gout not recognized as "refractory"
Symptom Signature: Frequent gout flares (≥3/year) + visible tophi + inadequate uric acid control
Ada Detection: Moderate-high capability to surface refractory gout patterns
Revenue: $100-120K per course; first-mover monopoly with no direct competitors

Strategic Recommendations

Engage Amgen Rare Disease Leadership: Contact Kave Niksefat (SVP Global Marketing & Access) to discuss pilot programs for UPLIZNA and TEPEZZA
Develop Diagnostic Signature Detection: Build Ada assessment logic to surface ptosis + diplopia (MG) and eye bulging + double vision (TED)
Prepare Pilot Proposal: Target 5-10K patient identification per year for UPLIZNA, 10-15K for TEPEZZA
Negotiate Pricing Model: Propose 8-12% of first-year drug revenue or alternative flat-fee-per-patient-found model
Explore Tier 2 (KRYSTEXXA): Second-priority engagement due to strong fit score and large underrecognized population

Key Risks

Risk Category	Probability	Impact	Description
Prolia Biosimilar Erosion	High	High	$1-2B annual revenue loss by 2027-2028 following Feb 2025 patent expiration
MariTide Phase 3 Failure	Medium	High	Phase 3 results expected early 2027; failure eliminates $5-10B+ peak sales potential
Enbrel Continued Decline	High	Medium	-33% YoY in 2025; patent expires Nov 2028; potential $1B+ loss by 2028
Obesity Market Saturation	Medium	Medium	MariTide enters 3-4 years after Wegovy/Zepbound; faces pricing pressure
U.S. Pricing Reform	Medium	Medium	IRA Medicare negotiation may impact products >9 years post-approval

References

Full citations available in the detailed markdown report. This HTML summary includes 79+ sources across academic literature, press releases, financial filings, regulatory documents, and industry analyses.

Amgen company overview and history. Multiple sources including Amgen.com, Wikipedia.
Amgen Q4 2025 and Full Year 2025 Financial Results. Press release, February 3, 2026
Amgen 2026 Guidance. PRNewswire, February 2026.
Rheumatoid Arthritis Diagnostic Delay. PMC Study
Osteoporosis Underdiagnosis. PMC Study
Familial Hypercholesterolemia Underdiagnosis. PMC Study
TEPEZZA Thyroid Eye Disease Treatment. WebMD
MariTide Phase 3 Trials. FierceBiotech
Amgen Biosimilars Growth. FiercePharma
Horizon Therapeutics Acquisition. FiercePharma, October 2023

Note: Complete reference list with 79+ sources available in full markdown report at ~/clawd/n8n_outputs/amgen/research_report.md